We Have Launched Drug Discovery Consulting Services

SOCIUM Inc. (https://socium.co.jp/) has launched a new consulting service to address your drug discovery challenges.

Through our two core business pillars—drug discovery and development using our proprietary AI platform (where two compounds have entered investigator-initiated clinical trials) and our phosphorylation array analysis service (which has yielded results for a wide range of challenges not only in oncology but also in other disease areas)—we have gained the experience and track record necessary to live up to the name “consulting.”

In reality, new drugs cannot be created by AI alone. Simply reading the literature and making predictions with AI is not enough to advance drug discovery. Our consulting services integrate our proprietary AI, computational science, and phosphorylation analysis technologies to

・Supporting not just “advice,” but “drug discovery,”
・Advancing drug discovery through technology, not just knowledge,
・Using world-first technologies to increase the success rate of drug discovery,
・Not just “formulating hypotheses,” but “proving them,”

and is one of the few hands-on drug discovery consulting firms in the world. For details on our current consulting services, please visit our website (https://socium.co.jp/conslting/).

Furthermore, one of our defining characteristics is our R&D-oriented approach, guided by the motto, “Difficulty fascinates us.” Therefore, we warmly welcome consulting requests for various challenges not listed on our website—even those that may seem “impossible.” In fact, our technology has steadily advanced through finding solutions to new challenges encountered during past contract analysis services and joint research projects.

We would be delighted if you would feel free to contact us via our contact page (https://socium.co.jp/contact/).